Loading
A phase 2 trial of Panobinostat in Leukaemia, run by Novartis Pharmaceuticals, completed.
Efficacy and Safety of Panobinostat (LBH589) in Patients With Refractory de Novo or Secondary Acute Myelogenous Leukemia (AML) is a phase 2 interventional study registered as NCT00880269 by Novartis Pharmaceuticals, with 59 participants recorded, started 2009-08 and reaching its primary completion in 2012-02. Interventions recorded: Panobinostat/LBH589. Conditions recorded: Refractory Leukemia, Acute Myelogenous Leukemia.
Linked to the drug Panobinostat because the registry names it among its interventions and Leukaemia among its conditions. Registry record only: no result has been read by an editor.
Shares Panobinostat, Novartis and the tag pipeline.
Shares Panobinostat and the tag pipeline.
Shares Novartis, Leukaemia (all types) and the tag pipeline.
Shares Leukaemia (all types) and the tag pipeline.
Shares Leukaemia (all types) and the tag pipeline.
Shares Novartis and the tag pipeline.
Shares Novartis and the tag pipeline.
Shares Leukaemia (all types) and the tag pipeline.